Trials / Completed
CompletedNCT03865732
Study of Adjunctive Ganaxolone Treatment in Female Children With Protocadherin 19 (PCDH19)-Related Epilepsy (Violet Study)
A Double-blind, Randomized, Placebo-controlled Trial of Adjunctive Ganaxolone Treatment in Female Children With Protocadherin 19 (PCDH19)-Related Epilepsy Followed by Long-term Open-label Treatment.
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 29 (actual)
- Sponsor
- Marinus Pharmaceuticals · Industry
- Sex
- Female
- Age
- 1 Year – 17 Years
- Healthy volunteers
- Not accepted
Summary
A clinical study to evaluate the efficacy, safety, and tolerability of adjunctive ganaxolone therapy compared to placebo for the treatment of seizures in female children and young adults with genetically confirmed PCDH19 gene mutation.
Detailed description
The Violet Study is a global, double-blind, placebo-controlled, Phase 2 clinical trial that plans to enroll approximately 25 female patients between the ages of 1 and 17 with a confirmed disease-related PCDH19 gene variant. Patients will undergo a baseline period before being randomized to receive, in addition to their existing anti-seizure treatment, either ganaxolone or placebo for 17 weeks. Following the treatment period, all patients that meet certain eligibility requirements will have the opportunity to receive ganaxolone in the open label phase of the study. The study's primary efficacy endpoint is percent reduction in seizures. Secondary outcome measures will include non-seizure-related endpoints to capture certain behavioral and sleep disturbances that have been seen in previous clinical studies with ganaxolone.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ganaxolone | active drug |
| DRUG | Placebo | inactive |
Timeline
- Start date
- 2019-05-17
- Primary completion
- 2021-01-19
- Completion
- 2022-06-20
- First posted
- 2019-03-07
- Last updated
- 2023-06-26
- Results posted
- 2022-09-08
Locations
12 sites across 5 countries: United States, Hungary, Italy, Netherlands, Poland
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03865732. Inclusion in this directory is not an endorsement.